On June 30, 2023, AMERICAN VANGUARD ($NYSE:AVD) reported their financial results for the second quarter of the fiscal year 2023. Total revenue had decreased by 10.3% compared to the same period in the previous year, amounting to USD 132.8 million. Net income for the quarter came to USD -1.0 million, a decrease of 6.8 million from Q2 of FY2022.
The company’s stock opened the day at $15.2 and closed at $14.4, a plunge of 16.4% from the previous day’s closing price of 17.2. This was a significant drop from the previous quarter’s average stock price of $17.2, indicating that the company is struggling to maintain its financial stability. The lower stock price may indicate investor apprehension in the company’s long-term prospects and future performance. Investors will be watching closely as AMERICAN VANGUARD continues to report its earnings results throughout the remainder of the fiscal year. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for American Vanguard. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for American Vanguard. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for American Vanguard. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for American Vanguard are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – American Vanguard Intrinsic Stock Value
At GoodWhale, we’ve conducted an analysis of AMERICAN VANGUARD‘s wellbeing. Using our proprietary Valuation Line, we calculated the intrinsic value of AMERICAN VANGUARD’s share to be around $19.6. Currently, the share is trading at $14.4, indicating it is undervalued by 26.6%. This suggests that buying AMERICAN VANGUARD’s share right now may be a good investment option. More…
Risk Rating Analysis
Star Chart Analysis
Some of its competitors are Sumitomo Chemical India Ltd, Sungbo Chemicals Co Ltd, Mangalore Chemicals & Fertilizers Ltd.
– Sumitomo Chemical India Ltd ($BSE:542920)
Sumitomo Chemical India Ltd is a chemical company with a market cap of 222.67B as of 2022. The company has a return on equity of 20.47%. Sumitomo Chemical India Ltd produces and sells a variety of chemicals, including pesticides, herbicides, insecticides, and fungicides. The company also manufactures and sells pharmaceuticals, plastics, rubber, and other chemicals. Sumitomo Chemical India Ltd has operations in India, Japan, and China.
– Sungbo Chemicals Co Ltd ($KOSE:003080)
Sungbo Chemicals Co Ltd is a South Korean company that manufactures and sells a variety of chemicals. The company has a market cap of $68.83 billion as of 2022 and a return on equity of 6.92%. Sungbo Chemicals Co Ltd is a publicly traded company on the Seoul Stock Exchange.
– Mangalore Chemicals & Fertilizers Ltd ($BSE:530011)
Mangalore Chemicals & Fertilizers Ltd. is an Indian chemical company based in Mangalore. The company produces fertilizers, pesticides and other chemicals. It is a public company listed on the Bombay Stock Exchange and the National Stock Exchange of India. The company has a market capitalization of 9.41 billion as of 2022 and a return on equity of 8.41%. The company was founded in 1976 and has its headquarters in Mangalore, Karnataka, India.
American Vanguard‘s second quarter earnings results for FY2023 were not encouraging as total revenue dropped 10.3% year-on-year. Net income was reported to be USD -1.0 million, compared to 6.8 million during the same period in FY2022. The company’s stock price reacted accordingly and dropped on the day of announcement.
Investors should carefully consider American Vanguard’s performance and outlook when making their investing decisions. They should pay attention to any potential risks, such as declining revenue, to determine whether or not the company is a good candidate for long-term investments.